Method of treating expressive language deficit in autistic humans
AssigneeAMS Therapeutics, LLC
InventorCharles E. Niesen
Life of this patent
Estimating the term…
Abstract
A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferably over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.
Claims21
A method of treating expressive language deficit in an autistic human, comprising:
- administering ethosuximide to an autistic human at a dosage and for a period of time sufficient to reduce the autistic human's expressive language deficit.
10-12. (canceled)
A method of improving expressive language skills in an autistic human, comprising:
- administering ethosuximide to an autistic human at a dosage and for a period of time sufficient to raise the autistic human's expressive language skills by at least 1 point on a 7-point scale, where 0=non-verbal, 1=echolalic, 2=single words, 3=phrases, 4=sentences, 5=spontaneous speech, and 6=mutual speech (true conversation with another person).
A method of treating expressive language deficit in an autistic, nonepileptic human, comprising:
- administering ethosuximide to an autistic, nonepileptic human at a dosage and for a period of time sufficient to reduce the autistic, nonepileptic human's expressive language deficit.
Dependencies are inferred from the claim text.